Stock OSL ONCOSIL MEDICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company OncoSil Medical Limited

Equities

OSL

AU000000OSL3

Pharmaceuticals

Market Closed - Australian S.E.
Other stock markets
 02:10:45 2024-04-19 am EDT 		5-day change 1st Jan Change
0.006 AUD -14.29% Intraday chart for OncoSil Medical Limited 0.00% -33.33%
Apr. 18 OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial MT
Apr. 16 OncoSil Medical Treats First Commercial Patient in Turkey with Implantable Pancreatic Cancer Device MT

Business Summary

OncoSil Medical Ltd is an Australia-based medical device company seeking to advance radiation for cancer patients. The Company is focused on the development and commercialization of its lead product candidate, OncoSil localized radiation therapy, for the treatment of pancreatic and distal cholangiocarcinoma. OncoSil is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient’s pancreatic tumors through an endoscopic ultrasound. OncoSil is a single-use brachytherapy device that has received breakthrough device designation in the European Union, the United Kingdom, and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy. OncoSil comprises phosphorous-32 microparticles suspended in a specially formulated diluent. OncoSil is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy.

Sales per Business

AUD in Million2022Weight2023Weight Delta
Device Development for New Medical Treatment
100.0 %
0 100.0 % 0 100.0 % +58.63%

Sales per region

AUD in Million2022Weight2023Weight Delta
Australia and New Zealand
69.6 %
0 100.0 % 0 69.6 % +10.40%
Europe
30.4 %
-- 0 30.4 % -

Managers

Managers TitleAgeSince
Nigel Lange CEO
 Chief Executive Officer - 20-05-03
Christian Cin DFI
 Director of Finance/CFO - 23-05-31
Jon Bell CTO
 Chief Tech/Sci/R&D Officer - -
Henk Tissing CTO
 Chief Tech/Sci/R&D Officer - -
David Turner CTO
 Chief Tech/Sci/R&D Officer - 20-12-31

Members of the board

Members of the board TitleAgeSince
Nigel Lange CEO
 Chief Executive Officer - 20-05-03
Douglas Cubbin CHM
 Chairman - 23-08-06
Gabriel Liberatore BRD
 Director/Board Member - 23-07-13

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 3,103,954,978 1,715,689,736 ( 55.27 %) 0 55.27 %

Shareholders

NameEquities%Valuation
Sarah Cameron
4.816 %
142,655,394 4.816 % 465 057 $
Titan Bioventures Management Pty Ltd.
0.3869 %
11,458,427 0.3869 % 37 354 $
Martin Cross
0.1523 %
4,510,965 0.1523 % 14 706 $

Company contact information

OncoSil Medical Ltd.

7 Eden Park Drive Level 5

2113, Macquarie Park

+

http://www.oncosil.com.au
address OncoSil Medical Limited(OSL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ONCOSIL MEDICAL LIMITED Stock OncoSil Medical Limited
-33.33% 10.17M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+24.60% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.08% 550B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.63% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.37% 317B
ABBVIE INC. Stock AbbVie Inc.
+7.38% 292B
ASTRAZENECA PLC Stock AstraZeneca PLC
+3.26% 211B
NOVARTIS AG Stock Novartis AG
+0.78% 203B
PFIZER, INC. Stock Pfizer, Inc.
-9.69% 144B
AMGEN INC. Stock Amgen Inc.
-6.63% 141B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. OSL Stock
  4. Company OncoSil Medical Limited